Angelini Pharma US. Revenue and Competitors
Estimated Revenue & Valuation
- Angelini Pharma US.'s estimated annual revenue is currently $14.1M per year.
- Angelini Pharma US.'s estimated revenue per employee is $243,000
Employee Data
- Angelini Pharma US. has 58 Employees.
- Angelini Pharma US. grew their employee count by -5% last year.
Angelini Pharma US.'s People
Name | Title | Email/Phone |
---|---|---|
1 | US Human Resources Head | Reveal Email/Phone |
Angelini Pharma US. Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $44.6M | 150 | 1% | N/A | N/A |
#2 | $573.8M | 1518 | 8% | N/A | N/A |
#3 | $66.5M | 224 | 8% | N/A | N/A |
#4 | $2.9M | 18 | 6% | N/A | N/A |
#5 | $17M | 70 | -3% | N/A | N/A |
#6 | $45.1M | 152 | 1% | N/A | N/A |
#7 | $14.8M | 61 | 11% | N/A | N/A |
#8 | $7.6M | 35 | 3% | N/A | N/A |
#9 | $5.1M | 27 | -4% | N/A | N/A |
#10 | $6.5M | 30 | 11% | N/A | N/A |
What Is Angelini Pharma US.?
Angelini Pharma Inc. has grown to become an international leader in the healthcare field. For more than two decades, the medical community has depended on our innovative dialysis and infection control products to assure their patients receive safe, effective, and reliable medical options. Over the last few years we have become recognized as a driving force in infection control, antisepsis, and disinfection markets -- offering unique, safe, and efficient solutions that make managing and treating patients easier, faster, and less costly. Angelini Pharma Inc. pursues its mission with knowledge, skill, and a close focus on ethics. Our name has become synonymous with guaranteed quality and safety. With a team of great talent and a culture of diversity and inclusiveness, we will continue to carry on this mission.
keywords:N/AN/A
Total Funding
58
Number of Employees
$14.1M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Angelini Pharma US. News
Angelini Pharma is committed to helping patients in the ... Cenobamate is commercially available in the US under the trademark XCOPRI®.12.
Cenobamate is approved in the United States for the treatment of ... and is marketed by Angelini Pharma under the brand name ONTOZRY®.
launch cenobamate this year through partner Angelini Pharma in major European countries such as France, Italy, Switzerland and Spain;.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $13.3M | 58 | 4% | N/A |
#2 | $6.8M | 58 | 7% | N/A |
#3 | $12.9M | 59 | N/A | N/A |
#4 | $17.2M | 59 | 20% | N/A |
#5 | $11.7M | 59 | -6% | N/A |